Nanotechnology for COVID-19 : Therapeutics and Vaccine Research
The current global health threat by the novel coronavirus disease 2019 (COVID-19) requires an urgent deployment of advanced therapeutic options available. The role of nanotechnology is highly relevant to counter this "virus" nano enemy. Nano intervention is discussed in terms of designing effective nanocarriers to counter the conventional limitations of antiviral and biological therapeutics. This strategy directs the safe and effective delivery of available therapeutic options using engineered nanocarriers, blocking the initial interactions of viral spike glycoprotein with host cell surface receptors, and disruption of virion construction. Controlling and eliminating the spread and reoccurrence of this pandemic demands a safe and effective vaccine strategy. Nanocarriers have potential to design risk-free and effective immunization strategies for severe acute respiratory syndrome coronavirus 2 vaccine candidates such as protein constructs and nucleic acids. We discuss recent as well as ongoing nanotechnology-based therapeutic and prophylactic strategies to fight against this pandemic, outlining the key areas for nanoscientists to step in.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
ACS nano - 14(2020), 7 vom: 28. Juli, Seite 7760-7782 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chauhan, Gaurav [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.09.2020 Date Revised 29.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acsnano.0c04006 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311495656 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311495656 | ||
| 003 | DE-627 | ||
| 005 | 20231225142358.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acsnano.0c04006 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1038.xml |
| 035 | |a (DE-627)NLM311495656 | ||
| 035 | |a (NLM)32571007 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chauhan, Gaurav |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Nanotechnology for COVID-19 |b Therapeutics and Vaccine Research |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.09.2020 | ||
| 500 | |a Date Revised 29.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The current global health threat by the novel coronavirus disease 2019 (COVID-19) requires an urgent deployment of advanced therapeutic options available. The role of nanotechnology is highly relevant to counter this "virus" nano enemy. Nano intervention is discussed in terms of designing effective nanocarriers to counter the conventional limitations of antiviral and biological therapeutics. This strategy directs the safe and effective delivery of available therapeutic options using engineered nanocarriers, blocking the initial interactions of viral spike glycoprotein with host cell surface receptors, and disruption of virion construction. Controlling and eliminating the spread and reoccurrence of this pandemic demands a safe and effective vaccine strategy. Nanocarriers have potential to design risk-free and effective immunization strategies for severe acute respiratory syndrome coronavirus 2 vaccine candidates such as protein constructs and nucleic acids. We discuss recent as well as ongoing nanotechnology-based therapeutic and prophylactic strategies to fight against this pandemic, outlining the key areas for nanoscientists to step in | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a combination drug delivery | |
| 650 | 4 | |a coronavirus disease 2019 | |
| 650 | 4 | |a immunopathology | |
| 650 | 4 | |a nanomedicine | |
| 650 | 4 | |a repurposed nanotechnology | |
| 650 | 4 | |a severe acute respiratory syndrome coronavirus 2 structure | |
| 650 | 4 | |a targeted therapeutics | |
| 650 | 4 | |a vaccine adjuvant nanoparticles | |
| 650 | 4 | |a vaccine nanocarriers | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Viral Vaccines |2 NLM | |
| 700 | 1 | |a Madou, Marc J |e verfasserin |4 aut | |
| 700 | 1 | |a Kalra, Sourav |e verfasserin |4 aut | |
| 700 | 1 | |a Chopra, Vianni |e verfasserin |4 aut | |
| 700 | 1 | |a Ghosh, Deepa |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez-Chapa, Sergio O |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ACS nano |d 2007 |g 14(2020), 7 vom: 28. Juli, Seite 7760-7782 |w (DE-627)NLM18248100X |x 1936-086X |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2020 |g number:7 |g day:28 |g month:07 |g pages:7760-7782 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acsnano.0c04006 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2020 |e 7 |b 28 |c 07 |h 7760-7782 | ||